Chimeric Therapeutics, a clinical-stage cell therapy company and an Australian leader in cell therapy, has entered a partnership with Be The Match BioTherapies, an organization offering supply chain solutions for companies developing and commercializing cell and gene therapies.

Be The Match BioTherapies provides end-to-end services designed to expedite collection, transport and delivery of cellular starting material and clinical drug product, which will support Chimeric’s expanded clinical development of CHM 1101 (CLTX CAR T).

CHM 1101 (CLTX CAR T) is currently being evaluated in a single-site phase 1 clinical trial to treat patients with recurrent or progressive glioblastoma. This new partnership with Be The Match BioTherapies will enable the accelerated expansion of the program to additional clinical trial sites.

To support the advancement of CHM 1101 (CLTX CAR T), Be The Match BioTherapies will draw on more than 30 years of experience in collection network, supply chain and logistics management developed by the National Marrow Donor Program (NMDP) /Be The Match. Be The Match BioTherapies plans to leverage its established relationships and resources, including its Quality System Audit Program (QSAP), to grow Chimeric’s network of apheresis centers and ensure the entire network is appropriately qualified, onboarded, trained and supervised in order to meet accelerated timelines for the trial.

“Be The Match BioTherapies is an ideal partner for us, extending the reach and resources of our experienced cell therapy team,” said Jennifer Chow, CEO, Chimeric Therapeutics. “With its focused mission and the NMDP/Be The Match’s 30 plus years of experience in managing the complexity and risks of cell therapy logistics, we believe that the team at Be The Match BioTherapies is uniquely positioned to support the expansion of the CHM 1101 (CLTX CAR T) development program.”

Chris McClain, senior vice president, sales and business development, Be The Match BioTherapies, said, “We are proud to partner with Chimeric and support its aggressive timeline by providing optimized solutions that focus on process improvement and standardization implementation to accelerate product development and delivery. We have a shared commitment to advance next-generation cell therapies for waiting patients, and we intend to help them achieve their targets.”